Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Assess the Incidence of Deep Vein Thrombosis (DVT) Following Prophylactic Intravenous Administration of Recombinant Human Antithrombin(rhAT) to Hereditary Antithrombin (AT) Deficient Patients in High Risk Situations.

NCT00056550 is registered in ClinicalTrials.gov with rEVO Biologics as lead sponsor.

NCT NCT00056550
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00056550 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Assess the Incidence of Deep Vein Thrombosis (DVT) Following Prophylactic Intravenous Administration of Recombinant Human Antithrombin(rhAT) to Hereditary Antithrombin (AT) Deficient Patients in High Risk Situations.
Lead sponsor
rEVO Biologics
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2002
Completion date
February 29, 2004
Enrollment
14 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

antithrombin deficiency, congenital